Back

MHRA Secures Funding to Develop AdvanceGxP Service

AdvanceGxP, a planned service offering early regulatory support for new medicines technologies, has received development and testing funding from the Office for Life Sciences, according to the Medicines and Healthcare products Regulatory Agency (MHRA). The service is not yet accepting applications.

The MHRA says the service is intended to help developers examine how Good Practice requirements might apply to their technologies. Its practical support would help identify compliance and regulatory questions before decisions on development, production or investment are finalised.

Advanced technologies for manufacturing medicines are the initial focus. The examples outlined by the regulator range from production in space to personalised treatments manufactured within or close to hospitals and clinics. Artificial intelligence, robotics and automation are also within the scope described by the MHRA.

According to the agency, developers working with emerging technologies may have few precedents, detailed guidance documents or case studies to consult when applying established Good Practice principles. The resulting uncertainty can concern validation, facilities and processes, the MHRA says.

The regulator says AdvanceGxP is designed to sit alongside its existing services and formal inspections, rather than replace them. Participation would neither constitute an inspection nor provide clearance ahead of one. The service would not prescribe a particular technical approach or assure participants of any subsequent inspection or regulatory result. The MHRA says its regulatory decisions would remain independent.

Arrangements governing eligibility and access are still being developed. The agency says it plans to restrict the scale of initial testing while it assesses demand, available capacity, participants’ experience and the support required. Organisations can register interest in helping with testing, but the MHRA says this is separate from applying for advice or regulatory support and offers no assurance of pilot participation.

According to the MHRA, participants would pay nothing for AdvanceGxP during testing and the pilot. Organisations would still incur applicable charges for any other MHRA services they use or require. If fees are introduced for AdvanceGxP later, the regulator says it would announce them before charging begins.

The agency published its announcement on 18 November 2026. Minister Chris McDonald announced the development on 17 November 2026 at the DIA-MHRA Global Summit in London, according to the MHRA.

* This article is based on publicly available information at the time of writing.